SynthesisBritish journal of cancer2010
Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review.
Synthesis in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Prognostic factors for patients with anal cancer treated with conformal radiotherapy-a systematic review.BMC cancer · 2022Pooled it
- HPV status and immunohistochemical analysis of p16, p53 and PD‑L1 expression as prognostic biomarkers in patients with squamous cell anal cancer receiving definitive radiotherapy/chemoradiotherapy.Oncology letters · 2024Article
- Molecular biomarkers, network biomarkers, and dynamic network biomarkers for diagnosis and prediction of rare diseases.Fundamental research · 2022Review
- Biomarkers in Anal Cancer: Current Status in Diagnosis, Disease Progression and Therapeutic Strategies.Biomedicines · 2022Review
- Molecular and immunophenotypic characterization of anal squamous cell carcinoma reveals distinct clinicopathologic groups associated with HPV and TP53 mutation status.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- A Prospective Cohort Study of Biomarkers in Squamous Cell Carcinoma of the Anal Canal (SCCAC) and their Influence on Treatment Outcomes.Journal of Cancer · 2021Article
- Review
- FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.Clinical colorectal cancer · 2019Article
- Systemic Therapies for Advanced Squamous Cell Anal Cancer.Current oncology reports · 2018Review
- HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma.BMC gastroenterology · 2018Article
- Biomarkers in anal cancer: from biological understanding to stratified treatment.British journal of cancer · 2017Review
- Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.British journal of cancer · 2016Article
- Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer.British journal of cancer · 2016Article
- Background and Current Treatment of Squamous Cell Carcinoma of the Anus.Oncology and therapy · 2016Review
- HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53.British journal of cancer · 2015Article
- Increased expression of oncogene-induced senescence markers during cervical squamous cell cancer development.International journal of clinical and experimental pathology · 2014Article
- Human papilloma virus and squamous cell carcinoma of the anus.Clinical Medicine Insights. Oncology · 2014Review
- Anal cancer: are we making progress?Current oncology reports · 2013Review
- High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy.Radiation oncology (London, England) · 2012Article
- Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients.British journal of cancer · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundrecent decades have seen combination chemoradiotherapy become the standard treatment for anal squamous cell carcinoma (SCC). However, the burden of this disease continues to rise, with only 10% of patients with metastatic disease surviving >2 years. Further insight into tumour characteristics and molecular biology may identify novel therapeutic targets. This systematic review examines current prognostic markers in SCC of the anus.
methodsan extensive literature search was performed to identify studies reporting on biomarkers in anal cancer in the context of clinical outcome following treatment primarily with chemoradiotherapy.
resultsin all, 21 studies were included. A total of 29 biomarkers were studied belonging to 9 different functional classes. Of these biomarkers, 13 were found to have an association with outcome in at least one study. The tumour-suppressor genes p53 and p21 were the only markers shown to be of prognostic value in more than one study.
conclusionsan array of biomarkers have been identified that correlate with survival following chemoradiotherapy in anal cancer. However, investigators are yet to identify a biomarker that has the ability to consistently predict outcome in this disease. Further studies are needed to elucidate whether these candidate biomarkers demonstrate their optimum value when they serve as targets for new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.